Tag Archive for: AbbVie

The response rate exceeded the prespecified efficacy threshold and suggests epcoritamab may hold its own against Roche’s rival CD3xCD20 bispecific Lunsumio, which won FDA approval in follicular lymphoma last year.

The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG’s experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc.

Coherus BioSciences Inc.said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc.’s Humira, its blockbuster rheumatoid arthritis drug.

More than 3,000 state and local governments will receive nearly $19 billion in payments from drugmakers and pharmacy chains in the most recent round of opioid settlements.

British drugmaker AstraZeneca (AZN.L) said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

Coherus BioSciences Inc. said on Thursday it plans to launch a biosimilar of AbbVie Inc’s (ABBV.N) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.

With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma.

AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said.

AbbVie Inc. on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker’s attempts to cushion the blow to sales from blockbuster Humira losing patent exclusivity.

AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.